Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Obscure X chromosome protein emerges as key driver in several cancers

A little-known protein encoded on the X chromosome is attracting growing attention for its potential role in cancer development and treatment.

5 Aug 2026

New ultrasound technique breaches blood brain barrier to treat gliomas

In a promising sign for the potential of focused sound waves to improve care for brain tumors, UVA Health researchers have determined that tumors called gliomas may be even more receptive to targeted drug delivery than normal brain tissue.

30 Jul 2026

Brain cancer Achilles heel revealed in the hours after surgery

Scientists in Britain and Spain have discovered critical windows after glioblastoma surgery when the brain’s defenses falter, creating a rare chance to deliver powerful treatments exactly where needed.

29 Jul 2026

UVA researchers develop a new experimental approach to target glioblastoma

University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer.

22 Jul 2026

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, suggests a study in preclinical models co-led by researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham.

12 Jul 2026

New study explains how brain tumors evolve to resist treatment

A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.

11 Jul 2026

Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma

Scientists have identified a promising new strategy to tackle one of the biggest obstacles in treating glioblastoma, one of the most aggressive form of brain cancer: resistance to chemotherapy.

9 Jul 2026

First-in-class experimental CAR T-cell therapy shows promise against solid tumors

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

2 Jul 2026

Study potential new therapeutic strategy for patients with ATRX-mutant gliomas

A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common genetic alterations in glioma rewires the cancer cell genome to fuel tumor progression, suggesting a potential new therapeutic strategy for patients with ATRX-mutant gliomas.

1 Jul 2026

CAR-T cell therapy shows potential to eliminate aggressive glioblastoma

A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and attack cancer, could be used to treat glioblastoma.

1 Jul 2026

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain tumors and the immune cells that help them grow.

1 Jul 2026

First-in-human trial tests safer T-cell therapy for pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors.

30 Jun 2026

Study uncovers sex-specific immune pathway driving glioblastoma growth

Researchers have identified a critical biological difference in how glioblastoma develops in male and female laboratory models, pinpointing an immune pathway that fuels tumor growth only in females.

23 Jun 2026

Sugar-coated nanoparticles extend survival in aggressive glioblastoma mouse model

Researchers at Oregon State University have potentially found a new way to treat the most aggressive form of brain cancer, glioblastoma, whose two-year survival rate is less than 30%.

23 Jun 2026

Preoperative radiation boosts immunotherapy response in brain metastases

A new study led by researchers at The University of Texas MD Anderson Cancer Center demonstrated that pre-operative radiation therapy for brain metastases not only targets tumor cells directly but also can activate immune pathways that can make tumors more receptive to immunotherapy.

17 Jun 2026

Dual-target CAR T therapy triggers broad immune response in brain cancer

Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival.

15 Jun 2026

Novel analysis identifies unique proliferation gene alterations in diverse cancer patients

New research to be presented today (Monday) at the annual conference of the European Society of Human Genetics shows that a cancer patient's genetic ancestry can have a significant effect both on how their disease progresses and their survival. In the largest study of its kind, researchers examined nearly 1,900 specific genetic changes in tumors in order to measure whether certain mutations were more common in patients with different historic geographic origins.

15 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Low-methionine diet shows promise against aggressive brain tumors

An unexpected lab observation led a team of scientists to discover how diet can influence survival in animal models of glioma, one of the most aggressive and deadly forms of brain cancer.

10 Jun 2026

Brain injury survivors face higher risk of brain cancer death

Daniel Daneshvar, MD, PhD, director of the HealthSpan Lab and Chief of the Department of Physical Medicine and Rehabilitation at Mass General Brigham, and Charlotte Luster, of the HealthSpan Lab, are the senior and lead authors of a paper published in Neuroepidemiology, "Brain Cancer Mortality following Traumatic Brain Injury (TBI): A TBI Model Systems Study."

10 Jun 2026